Takeda's QDENGA Vaccine Becomes First Dengue Vaccine Approved in India

Japanese pharmaceutical company Takeda's dengue vaccine, QDENGA, has made history as the first dengue vaccine to receive approval in India. According to Reuters, this approval is considered a significant milestone in the fight against dengue in the country. The vaccine is expected to provide protection against this widespread viral disease. Takeda's QDENGA vaccine had previously received approval in several other countries. The decision in India is seen as a step that will strengthen the company's presence in the Asian market. Dengue poses a serious public health problem, especially in tropical and subtropical regions. The approval granted by the Drug Controller General of India has paved the way for the use of QDENGA in the country. The vaccine is reported to be effective against all four serotypes of dengue, offering an important tool for controlling the disease. Takeda officials stated that they will collaborate with local health authorities to expand the vaccine's distribution in India. The company also plans to increase production capacity and accelerate approval processes in other countries. This is not investment advice.